rs,
change Plaza, Bandra-Kurla Complex, Bandra, Mumbai - 400 051. Symbol: HIKAL BSE Ltd., P J Towers, Dalal Street, Mumbai - 400 001. Scrip Code: 524735 Dear Sir/Madam, With reference to the subje
Rs. 448
the crop protection industry is showing signs of stabilization. In Q3 FY25, our revenue amounted to Rs. 448 Cr, with an EBITDA of Rs. 72 Cr, a 11% EBITDA growth on YoY basis. For the 9M FY25, revenue stood at
Rs. 72
s showing signs of stabilization. In Q3 FY25, our revenue amounted to Rs. 448 Cr, with an EBITDA of Rs. 72 Cr, a 11% EBITDA growth on YoY basis. For the 9M FY25, revenue stood at Rs. 1307 Cr, with an EBITDA
11%
ns of stabilization. In Q3 FY25, our revenue amounted to Rs. 448 Cr, with an EBITDA of Rs. 72 Cr, a 11% EBITDA growth on YoY basis. For the 9M FY25, revenue stood at Rs. 1307 Cr, with an EBITDA of Rs. 20
Rs. 1307
r, with an EBITDA of Rs. 72 Cr, a 11% EBITDA growth on YoY basis. For the 9M FY25, revenue stood at Rs. 1307 Cr, with an EBITDA of Rs. 205 Cr, a growth of 3% and 19% respectively. The stable raw materials pric
Rs. 205
a 11% EBITDA growth on YoY basis. For the 9M FY25, revenue stood at Rs. 1307 Cr, with an EBITDA of Rs. 205 Cr, a growth of 3% and 19% respectively. The stable raw materials prices, focused cost improvement i
3%
YoY basis. For the 9M FY25, revenue stood at Rs. 1307 Cr, with an EBITDA of Rs. 205 Cr, a growth of 3% and 19% respectively. The stable raw materials prices, focused cost improvement initiatives and int
19%
is. For the 9M FY25, revenue stood at Rs. 1307 Cr, with an EBITDA of Rs. 205 Cr, a growth of 3% and 19% respectively. The stable raw materials prices, focused cost improvement initiatives and intensified
Rs. 102
margin profile. Our focused business initiatives have resulted in increased operating cash flows of Rs. 102 Cr YoY on 9 months basis. Our Board of Directors has recommended an interim dividend of Rs. 0.60 per
Rs. 0.60
of Rs. 102 Cr YoY on 9 months basis. Our Board of Directors has recommended an interim dividend of Rs. 0.60 per share (30%). In Q3 FY25, our pharmaceutical revenue stood at Rs. 293 Cr with EBIT margin of 11.
30%
n 9 months basis. Our Board of Directors has recommended an interim dividend of Rs. 0.60 per share (30%). In Q3 FY25, our pharmaceutical revenue stood at Rs. 293 Cr with EBIT margin of 11.4%, an increas
Rs. 293
d an interim dividend of Rs. 0.60 per share (30%). In Q3 FY25, our pharmaceutical revenue stood at Rs. 293 Cr with EBIT margin of 11.4%, an increase of 449 bps, on a YoY basis. Our CDMO business continues to